MASTER TRANSACTION AGREEMENTMaster Transaction Agreement • February 22nd, 2023 • Bracebridge Capital, LLC • In vitro & in vivo diagnostic substances • New York
Quotient Holdings Finance Company Limited, an exempted company incorporated under the Laws of the Cayman Islands (the “Seller”), hereby covenants and agrees with you as follows:
BUSINESS AND ASSET TRANSFER AGREEMENT by and among Quotient Limited, Quotient Holdings Newco, LP and Quotient Holdings Finance Company Limited Dated as of February 16, 2023Business and Asset Transfer Agreement • February 22nd, 2023 • Bracebridge Capital, LLC • In vitro & in vivo diagnostic substances • New York
JOINT FILING AGREEMENTJoint Filing Agreement • April 27th, 2015 • Bracebridge Capital, LLC • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree, as of April 27, 2015, that only one statement containing the information required by Schedule 13G, and each amendment thereto, need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Pernix Therapeutics Holdings, Inc., and such statement to which this Joint Filing Agreement is attached as Exhibit 1 is filed on behalf of each of the undersigned.
JOINT FILING AGREEMENTJoint Filing Agreement • June 27th, 2022 • Bracebridge Capital, LLC • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree, as of June 24, 2022, that only one statement containing the information required by Schedule 13G, and each amendment thereto, need be filed with respect to the ownership by each of the undersigned of shares of common stock, par value $0.01 per share, of Mallinckrodt plc, and such statement to which this Joint Filing Agreement is attached as Exhibit 99.1 is filed on behalf of each of the undersigned.
Joint Filing AgreementJoint Filing Agreement • June 15th, 2023 • Bracebridge Capital, LLC • Blank checks
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree, as of June 14, 2023, that only one statement containing the information required by Schedule 13G, and each amendment thereto, need be filed with respect to the ownership by each of the undersigned of shares of common stock, par value $0.0001 per share, of Edify Acquisition Corp., and such statement to which this Joint Filing Agreement is attached as Exhibit 99.1 is filed on behalf of each of the undersigned.
JOINT FILING AGREEMENTJoint Filing Agreement • September 17th, 2021 • Bracebridge Capital, LLC • Biological products, (no disgnostic substances)
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree, as of September 17, 2021, that only one statement containing the information required by Schedule 13G, and each amendment thereto, need be filed with respect to the ownership by each of the undersigned of shares of common stock, par value $0.0001 per share, of Clarus Therapeutics Holdings, Inc., and such statement to which this Joint Filing Agreement is attached as Exhibit 99.1 is filed on behalf of each of the undersigned.
